The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
Background. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chem...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2011/290132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550381882703872 |
|---|---|
| author | Kazuhiro Usui Tomonori Ushijima Yoshiaki Tanaka Chiharu Tanai Hiromichi Noda Norifumi Abe Hajime Horiuchi Teruo Ishihara |
| author_facet | Kazuhiro Usui Tomonori Ushijima Yoshiaki Tanaka Chiharu Tanai Hiromichi Noda Norifumi Abe Hajime Horiuchi Teruo Ishihara |
| author_sort | Kazuhiro Usui |
| collection | DOAJ |
| description | Background. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however, the frequency of EGFR mutation in patients with ILD and the efficacy and safety of EGFR-TKI in patients with ILD and EGFR mutation are unknown.
Methods. We retrospectively reviewed the association of the EGFR mutation status of nonsmall cell lung cancer and pulmonary diseases. Based on high-resolution computed tomography (HRCT) performed at diagnosis of lung cancer, patients were categorized into three groups: normal, emphysema, and fibrosis.
Results. Of 198 patients with nonsmall cell lung cancer, we identified 52 (26.3%) patients with an EGFR mutation. EGFR mutations were identified in 43 (35.2%) of 122 patients with normal lungs, 8 (13.6%) of 59 with emphysema, and 1 (5.9%) of 17 with pulmonary fibrosis. Of the 52 patients with EGFR mutation, 43 patients received gefitinib. One patient with an EGFR mutation and fibrosis developed fatal ILD. There was not a significant difference in median overall survival from gefitinib treatment between never-smokers and smokers (797 days versus not reached; 𝑃=0.96).
Conclusions. Patients with sensitive EGFR mutation and normal lungs may benefit from an EGFR-TKI treatment even if they have smoking history. |
| format | Article |
| id | doaj-art-da0825cae47f42f68f590f3db5ff0f98 |
| institution | Kabale University |
| issn | 2090-1836 2090-1844 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-da0825cae47f42f68f590f3db5ff0f982025-02-03T06:06:59ZengWileyPulmonary Medicine2090-18362090-18442011-01-01201110.1155/2011/290132290132The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary DiseasesKazuhiro Usui0Tomonori Ushijima1Yoshiaki Tanaka2Chiharu Tanai3Hiromichi Noda4Norifumi Abe5Hajime Horiuchi6Teruo Ishihara7Division of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Diagnostic Pathology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Chest Surgery, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Diagnostic Pathology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanDivision of Respirology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa, Tokyo 141-0022, JapanBackground. Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however, the frequency of EGFR mutation in patients with ILD and the efficacy and safety of EGFR-TKI in patients with ILD and EGFR mutation are unknown. Methods. We retrospectively reviewed the association of the EGFR mutation status of nonsmall cell lung cancer and pulmonary diseases. Based on high-resolution computed tomography (HRCT) performed at diagnosis of lung cancer, patients were categorized into three groups: normal, emphysema, and fibrosis. Results. Of 198 patients with nonsmall cell lung cancer, we identified 52 (26.3%) patients with an EGFR mutation. EGFR mutations were identified in 43 (35.2%) of 122 patients with normal lungs, 8 (13.6%) of 59 with emphysema, and 1 (5.9%) of 17 with pulmonary fibrosis. Of the 52 patients with EGFR mutation, 43 patients received gefitinib. One patient with an EGFR mutation and fibrosis developed fatal ILD. There was not a significant difference in median overall survival from gefitinib treatment between never-smokers and smokers (797 days versus not reached; 𝑃=0.96). Conclusions. Patients with sensitive EGFR mutation and normal lungs may benefit from an EGFR-TKI treatment even if they have smoking history.http://dx.doi.org/10.1155/2011/290132 |
| spellingShingle | Kazuhiro Usui Tomonori Ushijima Yoshiaki Tanaka Chiharu Tanai Hiromichi Noda Norifumi Abe Hajime Horiuchi Teruo Ishihara The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases Pulmonary Medicine |
| title | The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases |
| title_full | The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases |
| title_fullStr | The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases |
| title_full_unstemmed | The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases |
| title_short | The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases |
| title_sort | frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases |
| url | http://dx.doi.org/10.1155/2011/290132 |
| work_keys_str_mv | AT kazuhirousui thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT tomonoriushijima thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT yoshiakitanaka thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT chiharutanai thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT hiromichinoda thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT norifumiabe thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT hajimehoriuchi thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT teruoishihara thefrequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT kazuhirousui frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT tomonoriushijima frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT yoshiakitanaka frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT chiharutanai frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT hiromichinoda frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT norifumiabe frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT hajimehoriuchi frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases AT teruoishihara frequencyofepidermalgrowthfactorreceptormutationofnonsmallcelllungcanceraccordingtotheunderlyingpulmonarydiseases |